$
2.110
-0.050(-2.310%)
  • Overview
  • Forecast
  • Valuation
Line
Line
|
Candle
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
2.250
Open
2.220
VWAP
2.13
Vol
135.29K
Mkt Cap
63.78M
Low
2.065
Amount
288.37K
EV/EBITDA(TTM)
8.03
Total Shares
31.78M
EV
86.51M
EV/OCF(TTM)
6.80
P/S(TTM)
0.37

Zynex, Inc. develops, manufactures, markets and sells medical devices used for pain management and rehabilitation, as well as non-invasive fluid, sepsis and laser-based pulse oximetry monitoring systems for use in hospitals. The Company’s devices are...Show More

Market Estimates

Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q1
FY2025Q2
FY2025Q3
30.75M
-33.92%
--
--
33.00M
-33.85%
--
--
35.80M
-28.35%
--
--
Estimates Revision
The market is revising Downward the revenue expectations for Zynex, Inc. (ZYXI) for FY2025, with the revenue forecasts being adjusted by -32.96% over the past three months. During the same period, the stock price has changed by -73.76%.
Revenue Estimates for FY2025
Revise Downward
down Image
-32.96%
In Past 3 Month
Stock Price
Go Down
down Image
-73.76%
In Past 3 Month
3 Analyst Rating
up Image
385.78% Upside
Wall Street analysts forecast ZYXI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ZYXI is 10.25 USD with a low forecast of 5.50 USD and a high forecast of 15.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
2 Hold
0 Sell
Moderate Buy
up Image
385.78% Upside
Current: 2.110
sliders
Low
5.50
Averages
10.25
High
15.00
HC Wainwright & Co.
Yi Chen
Strong Buy
Maintains
$17 → $15
2025-03-12
Reason
Ladenburg Thalmann
Jeffrey Cohen
Strong Buy
to
Hold
Downgrades
n/a
2025-03-12
Reason
Ladenburg downgraded Zynex to Neutral from Buy without a price target saying the company continues to adjust operationally amid revenue pressure.
RBC Capital
Shagun Singh
Buy
to
Hold
Downgrades
$11 → $5.5
2025-03-12
Reason
RBC Capital downgraded Zynex to Sector Perform from Outperform with a price target of $5.50, down from $11. The firm says the company's "disappointing update" on its Q4 earnings call suggests a lack of visibility into its operations and business outlook. Zynex called out slower than normal Q4 payments from certain payers and a notification by its largest payer, Tricare, of a temporary suspension of payments to review prior claims, the analyst tells investors in a research note. RBC cites the loss of the company's largest payer and potential risk of a "domino effect" for the downgrade.
HC Wainwright & Co.
Yi Chen
Strong Buy
Reiterates
$17
2024-12-06
Reason
HC Wainwright & Co.
Yi Chen
Strong Buy
Maintains
$16 → $17
2024-10-25
Reason
RBC Capital
Shagun Singh
Buy
Maintains
$12 → $11
2024-10-08
Reason
RBC Capital analyst Shagun Singh lowered the firm's price target on Zynex to $11 from $12 and keeps an Outperform rating on the shares as part of a broader research note previewing Q3 results. The firm's industry checks suggest that Q3 underlying utilization trends were positive despite typical summer seasonality driving a sequential step-down in elective procedures, the analyst tells investors in a research note. Investor sentiment is also positive for MedTech stocks going into the earnings season, and investors are likely to continue to chase winners and catalyst-driven names into year-end, RBC added.
HC Wainwright & Co.
Yi Chen
Strong Buy
Reiterates
$16
2024-09-04
Reason
RBC Capital
Shagun Singh
Buy
Maintains
$15 → $12
2024-07-26
Reason
HC Wainwright & Co.
Yi Chen
Strong Buy
Maintains
$21 → $16
2024-07-26
Reason
RBC Capital
Shagun Singh
Buy
Reiterates
$15
2024-06-14
Reason

Valuation Metrics

The current forward P/E ratio for Zynex Inc (ZYXI.O) is -4.41, compared to its 5-year average forward P/E of 28.71. For a more detailed relative valuation and DCF analysis to assess Zynex Inc 's fair value, click here.

Forward PE

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
28.71
Current PE
-4.41
Overvalued PE
43.53
Undervalued PE
13.88

Forward EV/EBITDA

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
17.66
Current EV/EBITDA
-7.06
Overvalued EV/EBITDA
31.27
Undervalued EV/EBITDA
4.06

Forward PS

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Undervalued
5Y Average PS
2.57
Current PS
0.50
Overvalued PS
4.13
Undervalued PS
1.00

Financials

Annual
Quarterly
FY2024Q3
YoY :
+0.10%
49.97M
Total Revenue
FY2024Q3
YoY :
-30.68%
3.80M
Operating Profit
FY2024Q3
YoY :
-33.72%
2.38M
Net Income after Tax
FY2024Q3
YoY :
-30.00%
0.07
EPS - Diluted
FY2024Q3
YoY :
-19.12%
7.00M
Free Cash Flow
FY2024Q3
YoY :
-1.52%
79.63
Gross Profit Margin - %
FY2024Q3
YoY :
-4.52%
8.02
FCF Margin - %
FY2024Q3
YoY :
-33.75%
4.77
Net Margin - %
FY2024Q3
YoY :
-64.68%
6.05
ROIC

Trading Trends

Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
148.3K
USD
2
3-6
Months
419.3K
USD
13
6-9
Months
35.5K
USD
2
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months

ZYXI News & Events

Events Timeline
2025-03-11 (ET)
2025-03-11
16:11:36
Zynex sees Q1 EPS (30c), consensus 6c
select
2025-03-11
16:10:01
Zynex reports Q4 EPS (2c), consensus 9c
select
2024-12-17 (ET)
2024-12-17
08:17:31
Zynex partnering with Veterans Affairs Medical Centers
select
2024-10-24 (ET)
2024-10-24
16:05:00
Zynex sees 2024 EPS at least 20c, consensus 20c
select
2024-10-24
16:04:17
Zynex sees Q4 EPS at least 9c, consensus 10c
select
2024-10-24
16:03:25
Zynex reports Q3 EPS 7c, consensus 6c
select
2024-09-03 (ET)
2024-09-03
09:17:00
Zynex obtains FDA clearance for new pain management device
select
News
7.0
04-07Globenewswire
Zynex, Inc. (ZYXI) Shares Under Pressure Amid Tricare Payment Halt, Dim Outlook, and Investor Lawsuit – Hagens Berman
7.0
04-07Globenewswire
Levi & Korsinsky Reminds Zynex, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 19, 2025 – ZYXI
7.0
04-07Globenewswire
DEADLINE ALERT for ZYXI, PPTA, UCTT, SEI: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions
7.0
04-07Globenewswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Zynex, Inc. of Class Action Lawsuit and Upcoming Deadlines - ZYXI
7.0
04-06Globenewswire
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Zynex, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ZYXI
7.0
04-06Globenewswire
Faruqi & Faruqi Reminds Zynex Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 19, 2025 - ZYXI
7.0
04-04PRnewswire
Class Action Filed Against Zynex, Inc. (ZYXI) Seeking Recovery for Investors - Contact Levi & Korsinsky
7.0
04-03PRnewswire
ZYXI Investors Have Opportunity to Lead Zynex, Inc. Securities Fraud Lawsuit
7.0
04-03Globenewswire
ROSEN, GLOBAL TRIAL COUNSEL, Encourages Zynex, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ZYXI
7.0
04-03PRnewswire
The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Zynex, Inc.(ZYXI) Shareholders
9.0
04-03Globenewswire
Zynex, Inc. (ZYXI) Shares Under Pressure Amid Tricare Payment Halt, Dim Outlook, and Investor Lawsuit – Hagens Berman
7.0
04-03Globenewswire
DEADLINE ALERT for TBBK, ZYXI, PPTA, and UCTT: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
7.0
04-03Globenewswire
Deadline Alert: Zynex, Inc. (ZYXI) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit
7.0
04-03Globenewswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Zynex, Inc. of Class Action Lawsuit and Upcoming Deadlines - ZYXI
7.0
04-02PRnewswire
ZYXI INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Zynex, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
7.0
04-02PRnewswire
Zynex, Inc. (ZYXI) Craters 51% On Possible Accounting Issues, Securities Class Action Filed - Hagens Berman
7.0
04-02Globenewswire
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zynex
7.0
04-01Globenewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Bancorp, Zynex, Perpetua, and TFI and Encourages Investors to Contact the Firm
7.0
04-01PRnewswire
Zynex, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before May 19, 2025 to Discuss Your Rights - ZYXI
7.0
04-01Globenewswire
Lost Money on Zynex, Inc. (ZYXI)? Join Class Action Suit Seeking Recovery – Contact Levi & Korsinsky

FAQ

arrow icon

What is Zynex Inc (ZYXI) stock price today?

The current price of ZYXI is 2.11 USD — it has decreased -2.31 % in the last trading day.

arrow icon

What is Zynex Inc (ZYXI)'s business?

arrow icon

What is the price predicton of ZYXI Stock?

arrow icon

What is Zynex Inc (ZYXI)'s revenue for the last quarter?

arrow icon

What is Zynex Inc (ZYXI)'s earnings per share (EPS) for the last quarter?

arrow icon

What changes have occurred in the market's expectations for Zynex Inc (ZYXI)'s fundamentals?

arrow icon

How many employees does Zynex Inc (ZYXI). have?

arrow icon

What is Zynex Inc (ZYXI) market cap?